The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease

A. Di Sabatino, N. Battista, P. Biancheri, C. Rapino, L. Rovedatti, G. Astarita, A. Vanoli, E. Dainese, M. Guerci, D. Piomelli, S. L F Pender, T. T. MacDonald, M. MacCarrone, G. R. Corazza

Research output: Contribution to journalArticle

Abstract

Activation of cannabinoid receptors (CBs) by endocannabinoids impacts on a number of gastrointestinal functions. Recent data indicate that CB1 agonists improve 2,4-dinitrobenzene sulfonic acid-induced colitis in mice, thus suggesting a role for the endocannabinoid agonist anandamide (AEA) in protecting the gut against inflammation. We here examined the gut endocannabinoid system in inflammatory bowel disease (IBD) patients, and investigated the ex vivo and in vitro effects of the non-hydrolysable AEA analog methanandamide (MAEA) on the mucosal proinflammatory response. The content of AEA, but not of 2-arachidonoyl-glycerol and N-palmitoylethanolamine, was significantly lower in inflamed than uninflamed IBD mucosa, and this was paralleled by lower activity of the AEA-synthesizing enzyme N-acyl-phosphatidylethanolamine-specific phospholipase D and higher activity of the AEA-degrading enzyme fatty acid amide hydrolase. MAEA significantly downregulated interferon-γ and tumor necrosis factor-α secretion by both organ culture biopsies and lamina propria mononuclear cells. Although these results are promising, further studies are needed to determine the role of cannabinoid pathways in gut inflammation.

Original languageEnglish
Pages (from-to)574-583
Number of pages10
JournalMucosal Immunology
Volume4
Issue number5
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Endocannabinoids
Cannabinoids
Inflammatory Bowel Diseases
Mucous Membrane
Inflammation
Cannabinoid Receptors
Phospholipase D
Sulfonic Acids
Organ Culture Techniques
Enzymes
Colitis
Interferons
Down-Regulation
Tumor Necrosis Factor-alpha
Biopsy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. / Di Sabatino, A.; Battista, N.; Biancheri, P.; Rapino, C.; Rovedatti, L.; Astarita, G.; Vanoli, A.; Dainese, E.; Guerci, M.; Piomelli, D.; Pender, S. L F; MacDonald, T. T.; MacCarrone, M.; Corazza, G. R.

In: Mucosal Immunology, Vol. 4, No. 5, 09.2011, p. 574-583.

Research output: Contribution to journalArticle

Di Sabatino, A, Battista, N, Biancheri, P, Rapino, C, Rovedatti, L, Astarita, G, Vanoli, A, Dainese, E, Guerci, M, Piomelli, D, Pender, SLF, MacDonald, TT, MacCarrone, M & Corazza, GR 2011, 'The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease', Mucosal Immunology, vol. 4, no. 5, pp. 574-583. https://doi.org/10.1038/mi.2011.18
Di Sabatino, A. ; Battista, N. ; Biancheri, P. ; Rapino, C. ; Rovedatti, L. ; Astarita, G. ; Vanoli, A. ; Dainese, E. ; Guerci, M. ; Piomelli, D. ; Pender, S. L F ; MacDonald, T. T. ; MacCarrone, M. ; Corazza, G. R. / The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. In: Mucosal Immunology. 2011 ; Vol. 4, No. 5. pp. 574-583.
@article{244fc0ff4ff54d51803244a239004949,
title = "The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease",
abstract = "Activation of cannabinoid receptors (CBs) by endocannabinoids impacts on a number of gastrointestinal functions. Recent data indicate that CB1 agonists improve 2,4-dinitrobenzene sulfonic acid-induced colitis in mice, thus suggesting a role for the endocannabinoid agonist anandamide (AEA) in protecting the gut against inflammation. We here examined the gut endocannabinoid system in inflammatory bowel disease (IBD) patients, and investigated the ex vivo and in vitro effects of the non-hydrolysable AEA analog methanandamide (MAEA) on the mucosal proinflammatory response. The content of AEA, but not of 2-arachidonoyl-glycerol and N-palmitoylethanolamine, was significantly lower in inflamed than uninflamed IBD mucosa, and this was paralleled by lower activity of the AEA-synthesizing enzyme N-acyl-phosphatidylethanolamine-specific phospholipase D and higher activity of the AEA-degrading enzyme fatty acid amide hydrolase. MAEA significantly downregulated interferon-γ and tumor necrosis factor-α secretion by both organ culture biopsies and lamina propria mononuclear cells. Although these results are promising, further studies are needed to determine the role of cannabinoid pathways in gut inflammation.",
author = "{Di Sabatino}, A. and N. Battista and P. Biancheri and C. Rapino and L. Rovedatti and G. Astarita and A. Vanoli and E. Dainese and M. Guerci and D. Piomelli and Pender, {S. L F} and MacDonald, {T. T.} and M. MacCarrone and Corazza, {G. R.}",
year = "2011",
month = "9",
doi = "10.1038/mi.2011.18",
language = "English",
volume = "4",
pages = "574--583",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease

AU - Di Sabatino, A.

AU - Battista, N.

AU - Biancheri, P.

AU - Rapino, C.

AU - Rovedatti, L.

AU - Astarita, G.

AU - Vanoli, A.

AU - Dainese, E.

AU - Guerci, M.

AU - Piomelli, D.

AU - Pender, S. L F

AU - MacDonald, T. T.

AU - MacCarrone, M.

AU - Corazza, G. R.

PY - 2011/9

Y1 - 2011/9

N2 - Activation of cannabinoid receptors (CBs) by endocannabinoids impacts on a number of gastrointestinal functions. Recent data indicate that CB1 agonists improve 2,4-dinitrobenzene sulfonic acid-induced colitis in mice, thus suggesting a role for the endocannabinoid agonist anandamide (AEA) in protecting the gut against inflammation. We here examined the gut endocannabinoid system in inflammatory bowel disease (IBD) patients, and investigated the ex vivo and in vitro effects of the non-hydrolysable AEA analog methanandamide (MAEA) on the mucosal proinflammatory response. The content of AEA, but not of 2-arachidonoyl-glycerol and N-palmitoylethanolamine, was significantly lower in inflamed than uninflamed IBD mucosa, and this was paralleled by lower activity of the AEA-synthesizing enzyme N-acyl-phosphatidylethanolamine-specific phospholipase D and higher activity of the AEA-degrading enzyme fatty acid amide hydrolase. MAEA significantly downregulated interferon-γ and tumor necrosis factor-α secretion by both organ culture biopsies and lamina propria mononuclear cells. Although these results are promising, further studies are needed to determine the role of cannabinoid pathways in gut inflammation.

AB - Activation of cannabinoid receptors (CBs) by endocannabinoids impacts on a number of gastrointestinal functions. Recent data indicate that CB1 agonists improve 2,4-dinitrobenzene sulfonic acid-induced colitis in mice, thus suggesting a role for the endocannabinoid agonist anandamide (AEA) in protecting the gut against inflammation. We here examined the gut endocannabinoid system in inflammatory bowel disease (IBD) patients, and investigated the ex vivo and in vitro effects of the non-hydrolysable AEA analog methanandamide (MAEA) on the mucosal proinflammatory response. The content of AEA, but not of 2-arachidonoyl-glycerol and N-palmitoylethanolamine, was significantly lower in inflamed than uninflamed IBD mucosa, and this was paralleled by lower activity of the AEA-synthesizing enzyme N-acyl-phosphatidylethanolamine-specific phospholipase D and higher activity of the AEA-degrading enzyme fatty acid amide hydrolase. MAEA significantly downregulated interferon-γ and tumor necrosis factor-α secretion by both organ culture biopsies and lamina propria mononuclear cells. Although these results are promising, further studies are needed to determine the role of cannabinoid pathways in gut inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84860390304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860390304&partnerID=8YFLogxK

U2 - 10.1038/mi.2011.18

DO - 10.1038/mi.2011.18

M3 - Article

C2 - 21471961

AN - SCOPUS:84860390304

VL - 4

SP - 574

EP - 583

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 5

ER -